398. Review of Mucormycosis Cases at the University of Colorado Hospital from 2012-2018 and Evaluation of Risk Factors and Appropriateness of Antifungal Prophylaxis
Session: Poster Abstract Session: Fungal Disease: Management and Outcomes
Thursday, October 4, 2018
Room: S Poster Hall


Health-care associated outbreaks of mucormycosis have been described in the literature.  In 2017, the University of Colorado Hospital (UCH) had an increased number of cases of mucormycosis.  The objective of this study was to evaluate possible risk factors and weather patterns associated with cases of mucormycosis diagnosed at UCH from 2012-2018 in order determine if the current antifungal prophylaxis used at UCH should be modified.



A retrospective cohort was conducted involving patients > 18 years old who were admitted to UCH between 2012-2018 and were diagnosed with proven or probable mucormycosis as defined by the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria.  Medical records were reviewed, and data was collected on risk factors, antifungal prophylaxis, and mortality outcome.  Weather data was collected from the National Centers for Environmental Information (NCEI)



25 cases of proven or probable mucormycosis were identified.  On average patients had at least 2 risk factors associated with mucormycosis.  The most common risk factors included diabetes mellitus (DM) (13 patients), hematologic malignancy or hematopoietic stem cell transplant (HSCT) (11 patients), use of immunosuppressing medications (11 patients), and invasive procedures. (9 patients).  At the time of diagnosis, only 6 patients were on an antifungal with mold activity.  8 patients died during hospitalization.  The distribution of cases over time was compared to weather data for Colorado.  A cluster of cases occurred in 2013 (6 cases) and in 2017 (8 cases).  A majority of cases were diagnosed during the summer and fall months with July being the month with the most number of cases.  There were higher levels of precipitation that occurred prior to or during the cluster of cases.



Cases of mucormycosis at UCH were associated with DM, hematologic malignancy/HSCT, use of immunosuppressive therapy, and invasive procedures.  The increase of cases seen 2013 and 2017 occurred in the summer and fall months after higher levels of precipitation were observed in Colorado.  Providers at UCH may consider modifying antifungal prophylaxis to include mold coverage in patients with >2 risk factors for mucormycosis who are admitted during the summer and fall.


Jessica Lum, MD, Infectious Diseases, University of Colorado Hospital, Aurora, CO and Michelle Barron, MD, Internal Medicine/Infectious Diseases, University of Colorado Denver, Aurora, CO


J. Lum, None

M. Barron, Astellas Pharma: Investigator , Research support .

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.